Authors: Bleeker, WA Hayes, VM Karrenbeld, A Hofstra, RMW Verlind, E Hermans, J Poppema, S Buys, CHCM Plukker, JTM

Citation: Wa. Bleeker et al., Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer, DIS COL REC, 44(3), 2001, pp. 358-363

Authors: Bleeker, WA Mulder, NH Hermans, J Otter, R Plukker, JTM

Citation: Wa. Bleeker et al., Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer (Br J Surg 2001; 88: 101-6) - Reply, BR J SURG, 88(8), 2001, pp. 1129-1129

Authors: Bleeker, WA Mulder, NH Hermans, J Otter, R Plukker, JTM

Citation: Wa. Bleeker et al., Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer, BR J SURG, 88(1), 2001, pp. 101-106

Authors: Bleeker, WA Mulder, NH Hermans, J Otter, R Plukker, JT

Citation: Wa. Bleeker et al., The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer, ANN ONCOL, 11(5), 2000, pp. 547-552

Authors: Bleeker, WA Hayes, VM Karrenbeld, A Hofstra, RMW Hermans, J Buys, CCM Plukker, JTM

Citation: Wa. Bleeker et al., Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer, AM J GASTRO, 95(10), 2000, pp. 2953-2957